Trial Profile
An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Abivertinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 31 Jan 2019 Status changed from recruiting to completed.
- 28 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 28 Jun 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.